Author: admin

  • Kirkland Advises CBC Group-Backed NovaBridge Biosciences on Acquisition of VIS-101 | News

    Kirkland & Ellis advised CBC Group-backed NovaBridge Biosciences (Nasdaq: NBP, formally known as I-Mab) on its acquisition of VIS-101, a novel bifunctional biologic targeting VEGF-A and ANG2. This transaction was closed on October 20, 2025, representing another successful practice of leading biotech companies using the NewCo model to acquire high-potential drug assets.

    NovaBridge Biosciences was rebranded from I-Mab, following the launch of its new model business model reflecting strategic transition to a global biotech platform. Leveraging CBC Group’s rich resources and global capabilities, NovaBridge Biosciences collaborates with world-leading innovators to select high-potential drug assets and accelerate their access to global patients. NovaBridge Biosciences advances the most promising innovative drugs across multiple therapeutic fields by establishing satellite subsidiaries focused on specific therapeutic areas or assets.

    VIS-101 is a novel bispecific molecule targeting VEGF-A and ANG2. It is a more potent molecule that could potentially provide more durable treatment benefits for patients with wet AMD, DME and retinal vein occlusion (RVO) than current standard of care. VIS-101 has completed initial safety and dose-escalation studies in both the US and China, and is currently undergoing a Phase 2 study in China. VIS-101 is anticipated to enter into a Phase 3 study in 2026.

    The acquisition was completed by a newly formed subsidiary Visara, a clinical-stage biopharmaceutical company focusing on the development of best-in-class ophthalmic therapeutics, launched with an approximately $37M capital infusion from NovaBridge Biosciences and the contribution by AffaMed Therapeutics (HK) Limited of its rights to develop, commercialize and otherwise exploit VIS-101. Upon completion, NovaBridge Biosciences is the majority shareholder of Visara, and Visara controls global rights to VS-101. NovaBridge Biosciences has also signed a separate assignment agreement with Everest Medicines (HKEX: 1952) pursuant to which Visara has assigned Everest the right to develop, commercialize and otherwise exploit VIS-101 in Singapore, Thailand, Malaysia, Indonesia, Vietnam, China, Korea and India.

    The Kirkland team included corporate lawyers Mengyu Lu, Jiayi Wang, Justin Zhou, Ryan Choi, Yuchen Han, Louis Zhou and Rock Liu.

    Continue Reading

  • Harry Potter and the Philosopher’s Stone by JK Rowling audiobook review – an all-star outing | Harry Potter

    Harry Potter and the Philosopher’s Stone by JK Rowling audiobook review – an all-star outing | Harry Potter

    It has become tradition for Audible to bring out the big guns in the run-up to Christmas and deliver star-studded adaptations of well-known novels; the last few years have brought terrific productions of Dickens’s Oliver Twist, Bleak House and…

    Continue Reading

  • Inside the Glamour Women of the Year Awards with Demi Moore, Tyla, Rachel Zegler, and Ms. Rachel

    Inside the Glamour Women of the Year Awards with Demi Moore, Tyla, Rachel Zegler, and Ms. Rachel

    “Sisterhood is about who you choose along the way,” Glamour’s global editorial director Samantha Barry told a hyped-up audience at The Plaza—although in a sweet move, her own big sister had flown from across the world to be there to support…

    Continue Reading

  • Raymond Chan: Building Global Momentum for Patient Navigation at London Global Cancer Week 2025

    Raymond Chan: Building Global Momentum for Patient Navigation at London Global Cancer Week 2025

    Raymond Chan, Deputy Vice-Chancellor of Research at Flinders University, shared a post by Global Cancer Support at the American Cancer (ACS Global) on LinkedIn, adding:

    “Pleased to join ACS Global at London Global Cancer Week…

    Continue Reading

  • Covid and Flu Can Triple Your Risk of Heart Attack | The Transmission

    Covid and Flu Can Triple Your Risk of Heart Attack | The Transmission

    NYT A new analysis adds to the research about the link between viral infections and heart disease. A number of viral infections, including flu, Covid-19 and shingles, are linked to an increased risk…

    Continue Reading

  • IND-A vs SA-A 2nd unofficial Test preview: More game time on offer for Indians before main event against the Proteas

    IND-A vs SA-A 2nd unofficial Test preview: More game time on offer for Indians before main event against the Proteas

    The ‘A’ tours that countries embark on are like shadow sojourns. Shadow, because these teams are filled with National-team aspirants and players who mirror the qualities of the nation’s first-choice XI, with the expectation being that they…

    Continue Reading

  • India among 12 nations confirmed for mixed-team event in Chennai

    India among 12 nations confirmed for mixed-team event in Chennai

    Twelve nations, including hosts India, defending champions Egypt and the runners-up from the last edition, Malaysia, will take part in the Squash World Cup 2025, to be held in Chennai from December 9 to 14.

    World Squash, the global governing body…

    Continue Reading

  • Google’s AI mode agents can snag event tickets for you now – here’s how

    Google’s AI mode agents can snag event tickets for you now – here’s how

    Screenshot by Lance Whitney/ZDNET

    Follow ZDNET: Add us as a preferred source on Google.


    ZDNET’s key takeaways

    • Google’s AI mode uses agents to help you book event tickets.
    • The agents can also find wellness spas and restaurant tables.
    • The skill is…

    Continue Reading

  • Pakistan’s Position on Morocco’s Autonomy Plan

    Pakistan’s Position on Morocco’s Autonomy Plan

    Rabat — Pakistan’s Ambassador to Morocco, Syed Adil Gilani, clarified his country’s abstention in the recent UN Security Council vote on Morocco’s Autonomy Plan for Western Sahara, stressing that Pakistan has consistently…

    Continue Reading

  • Drax power plant to go on earning ‘over £1m a day’ from burning wood pellets | Drax

    Drax power plant to go on earning ‘over £1m a day’ from burning wood pellets | Drax

    Britain’s biggest power plant will continue to earn more than £1m a day from burning wood pellets under a new government subsidy contract designed to halve its financial support, according to analysts.

    The Drax power plant in North Yorkshire is in line to earn £458.6m a year between 2027 and 2031 after the government agreed to extend its subsidies beyond 2026, according to analysts at Ember, a climate thinktank.

    The earnings are well below the £869m in subsidies handed to the Drax power plant last year for generating about 5% of the UK’s electricity from burning biomass after the government promised to curb the use of biomass in Britain’s power system.

    Under the new contract, Drax will be paid to run just over a quarter of the time, down sharply from almost two-thirds of time currently. But the price it will earn for each unit of electricity generated will rise.

    Officials have offered the power plant a guaranteed price of £157.50 for every megawatt-hour of electricity it generates between 2027 and 2031, in today’s prices, which could be higher with inflation.

    This would be higher than the current price of £142.24/MWh earned by the power plant, and double the current wholesale market price of electricity bought in advance, which is just over £78/MWh.

    When the deal was agreed in February, the energy minister, Michael Shanks, said the company’s subsidies had been cut because it “simply did not deliver a good enough deal for bill payers and enabled Drax to make unacceptably large profits”.

    Under the terms of the new contract, the company will have to switch to using 100% woody biomass from sustainable sources, up from the current level of 70%. The government threatened “substantial penalties” if Drax does not comply.

    Will Gardiner, the chief executive of Drax, said: “We are pleased to have agreed this new contract with the UK government, which will support UK energy security into the 2030s and deliver a net saving for consumers compared with alternative sources of dispatchable generation.

    “The agreement will support the rollout of intermittent renewable generation across the UK and provides options to ensure Drax Power Station continues to play a long-term role in the regional economy and UK energy system,” Gardiner said.

    The company claims that independent analysis, undertaken by consultants at Baringa, found that the deal will deliver savings of up to £3.1bn over the four-year term by avoiding the need to produce extra power generation capacity, and reducing the UK reliance on gas and interconnectors.

    skip past newsletter promotion

    Josie Murdoch, an analyst at Ember, said: “Although this new deal means Drax generation and subsidies will fall, the deal will still see substantial subsidies handed out to Drax every day, all while Drax remains the largest emitting power station in the UK.”

    Electricity generated from biomass is defined as carbon neutral in the UK’s carbon budgets but Ember has claimed that the power plant’s actual emissions are more than the next six most polluting power plants in the UK combined. The findings were dismissed by Drax as “flawed” and the company accused its authors of ignoring its “widely accepted and internationally recognised approach to carbon accounting”.

    Earlier this year, the FCA, the City watchdog, began an investigation into Drax over “historical statements” made about the sourcing of wood pellets to examine whether the company had complied with disclosure and transparency rules.

    Continue Reading